Export 23 results:
Author [ Title
Filters: Author is Edwards, Kathryn M [Clear All Filters]
“Antibody responses among adolescent females receiving two or three quadrivalent human papillomavirus vaccine doses at standard and prolonged intervals.”, Vaccine, vol. 36, no. 6, pp. 881-889, 2018.
, “AS03-Adjuvanted H5N1 Avian Influenza Vaccine Modulates Early Innate Immune Signatures in Human Peripheral Blood Mononuclear Cells.”, J Infect Dis, vol. 219, no. 11, pp. 1786-1798, 2019.
, “Caregiver and adolescent factors associated with delayed completion of the three-dose human papillomavirus vaccination series.”, Vaccine, vol. 36, no. 11, pp. 1491-1499, 2018.
, “Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine.”, Vaccine, vol. 34, no. 4, pp. 547-554, 2016.
, “Cell-Based Systems Biology Analysis of Human AS03-Adjuvanted H5N1 Avian Influenza Vaccine Responses: A Phase I Randomized Controlled Trial.”, PLoS One, vol. 12, no. 1, p. e0167488, 2017.
, “Clinical and immune responses to inactivated influenza A(H1N1)pdm09 vaccine in children.”, Pediatr Infect Dis J, vol. 33, no. 8, pp. 865-71, 2014.
, , “Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial.”, JAMA, vol. 314, no. 3, pp. 237-46, 2015.
, “Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults.”, J Infect Dis, vol. 197, no. 5, pp. 667-75, 2008.
, “Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older.”, Vaccine, vol. S0264-410X, no. 20, pp. 31504-31508, 2021.
, “Immunogenicity of an inactivated monovalent 2009 H1N1 influenza vaccine in pregnant women.”, J Infect Dis, vol. 204, no. 6, pp. 854-63, 2011.
, “Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.”, JAMA, vol. 312, no. 14, pp. 1420-8, 2014.
, “Impact of body mass index on immunogenicity of pandemic H1N1 vaccine in children and adults.”, J Infect Dis, vol. 210, no. 8, pp. 1270-4, 2014.
, “Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009.”, Vaccine, vol. 30, no. 28, pp. 4240-8, 2012.
, “Proteomics show antigen presentation processes in human immune cells after AS03-H5N1 vaccination.”, Proteomics, vol. 17, no. 12, 2017.
, “Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults.”, Hum Vaccin Immunother, vol. 9, no. 12, pp. 2548-57, 2013.
, “Safety and Immunogenicity of Full-Dose Trivalent Inactivated Influenza Vaccine (TIV) Compared With Half-Dose TIV Administered to Children 6 Through 35 Months of Age.”, J Pediatric Infect Dis Soc, vol. 4, no. 3, pp. 214-24, 2015.
, “Safety and immunogenicity of seasonal trivalent inactivated influenza vaccines in pregnant women.”, Vaccine, vol. 36, no. 52, pp. 8054-8061, 2018.
, “Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules.”, Pediatrics, vol. 137, no. 2, p. e20152603, 2016.
, “Safety and immunogenicity of three seasonal inactivated influenza vaccines among pregnant women and antibody persistence in their infants.”, Vaccine, vol. 38, no. 33, pp. 5355-5363, 2020.
, “Seroprevalence and Risk Factors for Cytomegalovirus Infections in Adolescent Females.”, J Pediatric Infect Dis Soc, vol. 2, no. 1, pp. 7-14, 2013.
, “Seroprevalence of cytomegalovirus (CMV) and risk factors for infection in adolescent males.”, Clin Infect Dis, vol. 51, no. 10, pp. e76-81, 2010.
, “Vaccination success rate and reaction profile with diluted and undiluted smallpox vaccine: a randomized controlled trial.”, JAMA, vol. 292, no. 10, pp. 1205-12, 2004.
,